NextCure (NXTC)

• Market cap: $38.9M
• 1 day: -6.18%
• 5 days: 6.23%
• 1 month: -18.46%
• 3 months: 15.16%
• 6 months: 113.27%
• Year to date: -16.49%
• 1 year: 15.88%
• 5 years: -92.68%
• 10 years: -95.36%
• Sector: Healthcare
• Industry: Biotechnology

About: NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.

Employees: 43